Abstract
Hyperhomocysteinemia (HHcy) is a significant and independent risk factor for cardiovascular disease (CVD). It has been reported that lowering plasma homocysteine (Hcy) levels improved endothelial dysfunction and reduced the incidence of major adverse events after percutaneous coronary intervention. We and others have provided experimental evidence supporting the hypothesis that Hcy is a causative factor for atherosclerosis. This article will discuss biological and molecular events related to cardiovascular pathological changes associated with HHcy.
Original language | English |
---|---|
Pages (from-to) | 25-31 |
Number of pages | 7 |
Journal | Drug Discovery Today: Disease Mechanisms |
Volume | 2 |
Issue number | 1 |
DOIs | |
State | Published - 2005 |
Externally published | Yes |